Does Rallies show 13F holders for CPRX?

Yes. Rallies tracks hedge fund and 13F ownership data for CPRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CPRX. It does not provide personalized investment advice.

CPRX (Catalyst Pharmaceuticals) Stock Analysis - Hedge Fund Holdings

Catalyst Pharmaceuticals (CPRX) is a publicly traded Healthcare sector company. As of May 20, 2026, CPRX trades at $31.05 with a market cap of $3.82B and a P/E ratio of 17.25. CPRX moved -0.03% today. Year to date, CPRX is +34.82%; over the trailing twelve months it is +26.72%. Its 52-week range spans $19.05 to $32.56. Analyst consensus is buy with an average price target of $33.10. Rallies surfaces CPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CPRX stock?

Hedge funds tracked by Rallies that own CPRX include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Catalyst Pharmaceuticals.

CPRX Key Metrics

Key financial metrics for CPRX
Metric	Value
Price	$31.05
Market Cap	$3.82B
P/E Ratio	17.25
EPS	$1.81
Dividend Yield	0.00%
52-Week High	$32.56
52-Week Low	$19.05
Volume	2.75M
Avg Volume	0
Revenue (TTM)	$596.96M
Net Income	$221.32M
Gross Margin	85.96%

Top Hedge Funds Holding CPRX

Orbimed Advisors holds 416.90K shares of CPRX, changed +0.00% as of Jun 30, 2025.
Centerbook Partners holds 48.46K shares of CPRX, changed +306.99% as of Dec 31, 2025.

Latest CPRX News

Catalyst Pharmaceuticals' $31.50 Share Deal Faces Fairness Probe — May 19, 2026
Catalyst Pharmaceuticals Q1 Revenues Rise 5.6% to $149.3M as AGAMREE Jumps 66.6% — May 11, 2026
Angelini to Buy Catalyst Pharmaceuticals for $4.1 Billion at 70% Premium — May 11, 2026
Law Firm Probes Catalyst Pharmaceuticals’ $31.50-Per-Share Sale to Angelini Pharma — May 8, 2026
Angelini Pharma to Buy Catalyst for $4.1 B, 21% Premium at $31.50 — May 8, 2026

Recent CPRX Insider Trades

Harper Molly sold 15.53K (~$360.20K) on Dec 12, 2025.
Harper Molly sold 4.47K (~$106.16K) on Dec 12, 2025.
Harper Molly sold 6.75K (~$155.56K) on Dec 12, 2025.

CPRX Analyst Consensus

7 analysts cover CPRX: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $33.10.

Common questions about CPRX

Who owns CPRX stock?: Hedge funds tracked by Rallies that own CPRX include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Catalyst Pharmaceuticals.
Does Rallies show 13F holders for CPRX?: Yes. Rallies tracks hedge fund and 13F ownership data for CPRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CPRX. It does not provide personalized investment advice.